State‐of‐the‐Art Clinical Article: Pharmacokinetic/Pharmacodynamic Parameters: Rationale for Antibacterial Dosing of Mice and Men
The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
Investigations over the past 20 years have demonstrated that antibacterials can vary markedly in the time course of antimicrobial activity. These differences in pharmacodynamic activity have implications for optimal dosage regimens. The results of more recent studies suggest that the magnitude of the pharmacokinetic/pharmacodynamic parameters required for efficacy are relatively similar in animal infection models and in human infections. However, there is still much to learn. Additional studies are needed to further correlate pharmacokinetic/pharmacodynamic parameters for many antibacterials with therapeutic efficacy in a variety of animal infection models and in human infections. The potential value of using pharmacokinetic/pharmacodynamic parameters as guides for establishing optimal dosing regimens for new and old drugs and for new emerging pathogens and resistant organisms, for setting susceptibility breakpoints, and for reducing the cost of drug development should make the continuing search for the therapeutic rationale of antibacterial dosing of mice and men worthwhile.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Moore, R. D., Lietman, P. S., & Smith, C. R. (1987) · Journal of Infectious Diseases · doi:10.1093/infdis/155.1.93 · Cited by 1,139 · cited 1×
“However, the opposite was observed in the major clinical trials correlating pharmacokinetic/pharmacodynamic parameters with the therapeutic efficacy of aminoglycosides [56].”
Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients
Forrest, A., Nix, D. E., Ballow, C. H., Goss, T. F., Birmingham, M. C., & Schentag, J. J. (1993) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.37.5.1073 · Cited by 1,101 · cited 2×
“[52] found that a 24-hour AUC/MIC value of > 125 was associated with satisfactory outcome for seriously ill patients treated with intravenous ciprofloxacin.”
Pallares, R., Liñares, J., Vadillo, M., Cabellos, C., Manresa, F., Viladrich, P. F., Martin, R., & Gudiol, F. (1995) · New England Journal of Medicine · doi:10.1056/nejm199508243330802 · Cited by 773
Correlation of Antimicrobial Pharmacokinetic Parameters with Therapeutic Efficacy in an Animal Model
Vogelman, B., Gudmundsson, S., Leggett, J., Turnidge, J., Ebert, S., & Craig, W. A. (1988) · The Journal of Infectious Diseases · doi:10.1093/infdis/158.4.831 · Cited by 720 · cited 3×
“need to exceed the MIC for 100% of the dosing interval to exert a significant antibacterial effect [25-27, 36].”
Self-citationCraig, W. A. (1995) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/0732-8893(95)00053-d · Cited by 618 · cited 5×
“Several investigators have used multiple dosage regimens in animal infection models to correlate specific pharmacokinetic/pharmacodynamic parameters with the efficacy of various antibacterials against both gram-positive and gram-negative bacilli [9, 25-31].”
InfluentialSelf-citationBlaser, J., Stone, B. B., Groner, M. C., & Zinner, S. H. (1987) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.31.7.1054 · Cited by 481
Pharmacokinetics and pharmacodynamics of antibiotics in otitis media
CRAIG, W. A., & ANDES, D. (1996) · The Pediatric Infectious Disease Journal · doi:10.1097/00006454-199603000-00015 · Cited by 435 · cited 3×
“pneumoniae and Haemophilus influenzae in patients with otitis media [38, 43].”
InfluentialSelf-citationDrusano, G. L., Johnson, D. E., Rosen, M., & Standiford, H. C. (1993) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.37.3.483 · Cited by 426 · cited 2×
“there is a significant risk of the emergence of resistant subpopulations [29].”
Leggett, J. E., Fantin, B., Ebert, S., Totsuka, K., Vogelman, B., Calame, W., Mattie, H., & Craig, W. A. (1989) · Journal of Infectious Diseases · doi:10.1093/infdis/159.2.281 · Cited by 354
Self-citationKinetics of antimicrobial activity
Vogelman, B., & Craig, W. A. (1986) · The Journal of Pediatrics · doi:10.1016/s0022-3476(86)80754-5 · Cited by 315 · cited 4×
“PAE refers to the persistent suppression of bacterial growth following exposure to an antimicrobial [2, 7, 10].”
InfluentialSelf-citation
Cited by
Items 601–700 of 1,003
A Randomized Trial of Loading Vancomycin in the Emergency Department
Rosini, J. M., Laughner, J., Levine, B. J., Papas, M. A., Reinhardt, J. F., & Jasani, N. B. (2014) · Annals of Pharmacotherapy · doi:10.1177/1060028014556813 · Cited by 61
Necessity of Bumped Kinase Inhibitor Gastrointestinal Exposure in Treating Cryptosporidium Infection
Arnold, S. L. M., Choi, R., Hulverson, M. A., Schaefer, D. A., Vinayak, S., Vidadala, R. S. R., McCloskey, M. C., Whitman, G. R., Huang, W., Barrett, L. K., et al. (2017) · The Journal of Infectious Diseases · doi:10.1093/infdis/jix247 · Cited by 61
“56 • JID 2017:216 (1 July) • Arnold et al β-lactams [9, 10] and fluoroquinolones [11–13].”
BackgroundWagenlehner, F., Wydra, S., Onda, H., Kinzig‐Schippers, M., Sörgel, F., & Naber, K. G. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.12.3789-3794.2003 · Cited by 61
“This parameter is independent of the dosing interval (10).”
BackgroundRedefining Multidrug-Resistant Tuberculosis Based on Clinical Response to Combination Therapy
Gumbo, T., Pasipanodya, J. G., Wash, P., Burger, A., & McIlleron, H. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.03549-14 · Cited by 60
Andes, D. R., & Lepak, A. J. (2017) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2017.09.004 · Cited by 60
Intravenous Push Administration of Antibiotics: Literature and Considerations
Spencer, S. H., Ipema, H. J., Hartke, P. L., Krueger, C., Rodriguez, R. W., Gross, A. E., & Gabay, M. P. (2018) · Hospital Pharmacy · doi:10.1177/0018578718760257 · Cited by 60
A New Modeling Approach to the Effect of Antimicrobial Agents on Heterogeneous Microbial Populations
Nikolaou, M., & Tam, V. H. (2005) · Journal of Mathematical Biology · doi:10.1007/s00285-005-0350-6 · Cited by 60
“agent concentration that achieves this is the routinely and widely used minimal inhibitory concentration (MIC) [2, 11].”
MethodZobell, J. T., Waters, C. D., Young, D. C., Stockmann, C. R., Ampofo, K., Sherwin, C. M. T., & Spigarelli, M. G. (2012) · Pediatric Pulmonology · doi:10.1002/ppul.22669 · Cited by 60
“, three to four times MIC) and when the penicillin concentrations remain above the MIC for 50–60% of the dosing interval.(10,11,13) The most common adverse effect of penicillins is hypersensitivity reactions (i.”
BackgroundIntravitreal vancomycin and gentamicin concentrations in patients with postoperative endophthalmitis
Gan, I. M., van Dissel, J. T., Beekhuis, W. H., Swart, W., & van Meurs, J. C. (2001) · British Journal of Ophthalmology · doi:10.1136/bjo.85.11.1289 · Cited by 60
Failure of Treatment of Pneumonia Associated with Highly Resistant Pneumococci in a Child
Dowell, S. F., Smith, T., Leversedge, K., & Snitzer, J. A. (1999) · Clinical Infectious Diseases · doi:10.1086/588389 · Cited by 60
ANTIMICROBIAL AND ANTI-INFLAMMATORY TREATMENT OF BACTERIAL MENINGITIS
Sáez‐Llorens, X., & McCracken, G. H. (1999) · Infectious Disease Clinics of North America · doi:10.1016/s0891-5520(05)70097-0 · Cited by 60
(2012) · PubMed · Cited by 59
Two-Drug Antimicrobial Chemotherapy: A Mathematical Model and Experiments with Mycobacterium marinum
Ankomah, P., & Levin, B. R. (2012) · PLoS Pathogens · doi:10.1371/journal.ppat.1002487 · Cited by 59
“One approach to improving the efficacy of single drug therapy has been to design treatment regimes based on in vivo data of the changes in the concentration of the antibiotic, pharmacokinetics (PK), and in vitro data on the relationship between the concentration of the drug and the rate of growth/death of the bacteria…”
BackgroundTorres, A., Mouton, J. W., & Pea, F. (2016) · Clinical Pharmacokinetics · doi:10.1007/s40262-016-0418-z · Cited by 59
“The main pharmacokinetic/pharmacodynamic index shown to correlate with therapeutic efficacy is the length of time that the unbound drug concentration exceeds the minimum inhibitory concentration (fT[MIC), typically expressed as a proportion of the dosing interval (%fT[MIC) [54].”
BackgroundLallemand, E. A., Lacroix, M. Z., Toutain, P., Boullier, S., Ferran, A. A., & Bousquet‐mélou, A. (2016) · Frontiers in Microbiology · doi:10.3389/fmicb.2016.02051 · Cited by 59
“PK/PD indices such as AUC/MIC are used to establish optimal dosing regimens and are calculated from the MIC reported for the pathogen (Craig, 1998).”
BackgroundMethodLee, Y. R., Miller, P. D., Alzghari, S. K., Blanco, D. D., Hager, J. D., & Kuntz, K. S. (2017) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/s13318-017-0439-5 · Cited by 59
“Because drug concentration in the body ultimately depends on pharmacokinetic parameters, such as clearance and volume of distribution (Vd), achieving target beta-lactam concentrations above the MIC for the desired amount of time in critically ill patients can be difficult due to altered pharmacokinetics in this patien…”
BackgroundHeil, E. L., Nicolau, D. P., Farkas, A., Roberts, J. A., & Thom, K. A. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01008-18 · Cited by 59
Ceftriaxone Therapy for Staphylococcal Osteomyelitis: A Review
Guglielmo, B. J., Luber, A., Paletta, D., & Jacobs, R. A. (2000) · Clinical Infectious Diseases · doi:10.1086/313620 · Cited by 59
“It is a free antimicrobial that is microbiologically active [7], and free levels of b-lactams should remain above the MIC for most of the dosing interval [8].”
BackgroundMangalore, R. P., Peel, T. N., Udy, A. A., & Peleg, A. Y. (2023) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkad223 · Cited by 58
Bacteraemic Pneumococcal Pneumonia: Current Therapeutic Options
Feldman, C. H., & Anderson, R. (2011) · Drugs · doi:10.2165/11585310-000000000-00000 · Cited by 58
“This has been discussed in a number of review articles and is described more fully below ([85-87]).”
BackgroundHousman, S. T., Crandon, J. L., Nichols, W. W., & Nicolau, D. P. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02161-13 · Cited by 58
“Based on these observations, efficacy would be expected when the ELF fT MIC is less than the standard pharmacodynamic target of 60% for -lactams in the blood (16).”
BackgroundTolerance of subcutaneously administered antibiotics: a French national prospective study
Baudron, C. R., Forestier, E., Fraisse, T., Gaillat, J., de Wazières, B., Pagani, L., Ingrand, I., Bernard, L., Gavazzi, G., & Paccalin, M. (2016) · Age and Ageing · doi:10.1093/ageing/afw143 · Cited by 58
“In fact, the area under the curve (AUC) and the time over the minimal inhibitory concentration are quite similar between IV and SC routes [18], as illustrated by Frasca et al.”
BackgroundKawaguchi, N., Katsube, T., ECHOLS, R. M., & Wajima, T. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01391-17 · Cited by 58
“concentration in plasma exceeds the minimum inhibitory concentration (MIC) 51 (fT>MIC) (5-7) as has been described with other cephalosporins (8, 9).”
Pharmacodynamics of the New Des-F(6)-QuinoloneGarenoxacin in a Murine Thigh InfectionModel
Andes, D. R., & Craig, W. A. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.12.3935-3941.2003 · Cited by 58
Self-citationChoi, G. Y. S., Gomersall, C. D., Lipman, J., Wong, A. S. Y., Joynt, G. M., Leung, P., Ramsay, S., & Ho, O. M. (2004) · International Journal of Antimicrobial Agents · doi:10.1016/s0924-8579(04)00242-0 · Cited by 58
Murillo, Ó., Garrigós, C., Pachón, M. E., Euba, G., Verdaguer, R., Cabellos, C., Cabo, J., Gudiol, F., & Ariza, J. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00208-09 · Cited by 58
Antimicrobial agents in the treatment of bacterial meningitis
Sinner, S. W., & Tunkel, A. R. (2004) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2004.04.005 · Cited by 58
“In in vitro studies, most antibacterial agents display a significant postantibiotic effect against gram-positive organisms, whereas only aminoglycosides, fluoroquinolones, and carbapenems exert a postantibiotic effect against gram-negative organisms [30].”
BackgroundSprandel, K. A., Drusano, G. L., Hecht, D. W., Rotschafer, J. C., Danziger, L. H., & Rodvold, K. A. (2006) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2006.06.013 · Cited by 58
“Although there are no established pharmacokinetic/pharmacodynamic parameters correlated with the efficacy for metronidazole in the treatment of anaerobic infections, we chose to use the AUC/MIC ratio because this parameter is often one of the parameters correlated with the efficacy of antimicrobials with similar pharm…”
BackgroundMethodCohen, E., Dadashev, A., Drucker, M., Samra, Z., Rubinstein, E., & Garty, M. (2002) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/49.1.155 · Cited by 58
Vinks, A. A. T. M. M., van Rossem, R. N., Mathôt, R. A. A., Heijerman, H. G. M., & Mouton, J. W. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01522-06 · Cited by 58
“For different drug classes PD indices such as the exposure of unbound free (f) drug in relation to the MIC (fAUC/MIC or fT MIC) have been shown to correlate well with efficacy (11) and now contribute significantly to the establishment of MIC breakpoints that differentiate between high and low probabilities of cure (1).”
BackgroundInfluence of pharmacokinetics/pharmacodynamics of antibacterials in their dosing regimen selection
Scaglione, F., & Paraboni, L. (2006) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.4.3.479 · Cited by 58
Outpatient Parenteral Antimicrobial Therapy (OPAT): a review of experience at Auckland Hospital.
Upton, A., Ellis-Pegler, R. B., & Woodhouse, A. F. (2004) · PubMed · Cited by 58
Pharmacodynamics of Antimicrobials: General Concepts and Applications
Craig, W. A. (2007) · Infectious disease and therapy · doi:10.3109/9781420017137.001 · Cited by 58
Self-citationFukumoto, R., Cary, L. H., Gorbunov, N. V., Lombardini, E., Elliott, T. B., & Kiang, J. G. (2013) · PLoS ONE · doi:10.1371/journal.pone.0058389 · Cited by 57
“It is well tolerated, distributes rapidly in tissues, and has similar half-lives in mice [35,36,37] and humans [33], and is readily available in several formulations for oral, intravenous, intraperitoneal, and topical routes.”
BackgroundDrusano, G. L. (2005) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.2005.25.12part2.150s · Cited by 57
Lepak, A. J., Marchillo, K., Pichereau, S., Craig, W. A., & Andes, D. R. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01303-12 · Cited by 57
“These approaches have proven useful in guiding design of effective drug regimens in humans and the development of susceptibility breakpoints (1, 2, 17, 21, 40, 41, 45).”
BackgroundSelf-citationAntibiotics in Necrotizing Soft Tissue Infections
Urbina, T., Razazi, K., Ourghanlian, C., Woerther, P., Chosidow, O., Lepeule, R., & de Prost, N. (2021) · Antibiotics · doi:10.3390/antibiotics10091104 · Cited by 57
“Convincing in vitro, animal and clinical data also suggest that microbiological success may be optimal when serum β-lactam concentrations are maintained above 4 × MIC during the entire time frame [65–69].”
BackgroundInfluentialPharmacokinetics and Pharmacodynamics of Antifungals in Children and their Clinical Implications
Stockmann, C. R., Constance, J. E., Roberts, J. K., Olson, J. A., Doby, E. H., Ampofo, K., Stiers, J., Spigarelli, M. G., & Sherwin, C. M. T. (2014) · Clinical Pharmacokinetics · doi:10.1007/s40262-014-0139-0 · Cited by 57
“Additionally, extensive studies conducted with antibacterials have demonstrated that the correlation between pharmacodynamic target attainment and clinical outcomes is remarkably conserved across species, dosing intervals and infection foci [22, 23].”
BackgroundBooker, B. M., Smith, P. F., Forrest, A., Bullock, J. M., Kelchlin, P. A., Bhavnani, S. M., Jones, R. N., & Ambrose, P. G. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.5.1775-1781.2005 · Cited by 57
“Findings from in vitro and animals models are in agreement with clinical data, where fAUC0–24/ MIC ratios of 125 are associated with optimal fluoroquinolone activity for gram-negative bacilli (3, 5, 6, 9, 11, 16, 22, 28).”
BackgroundResultDoern, G. V., Pfaller, M. A., Erwin, M. E., Brueggemann, A. B., & Jones, R. (1998) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/s0732-8893(98)00081-9 · Cited by 57
Jacobs, M. R. (2002) · Clinical Infectious Diseases · doi:10.1086/341980 · Cited by 57
Pulmonary Penetration of Piperacillin and Tazobactam in Critically Ill Patients
Felton, T., McCalman, K., Malagon, I. L., Isalska, B. J., Whalley, S., Goodwin, J., Bentley, A. M., & Hope, W. W. (2014) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2014.131 · Cited by 56
Moriyama, B., Henning, S. A., Childs, R. W., Holland, S. M., Anderson, V., Morris, J. C., Wilson, W. H., Drusano, G. L., & Walsh, T. J. (2010) · Annals of Pharmacotherapy · doi:10.1345/aph.1m717 · Cited by 56
Khachman, D., Conil, J., Georges, B., Saivin, S., Houin, G., Toutain, P., & Laffont, C. M. (2011) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkr220 · Cited by 55
Gómez‐Junyent, J., Benavent, E., Sierra, Y., Haj, C. E., Soldevila, L., Torrejón, B., Rigo-Bonnin, R. F., Tubau, F., Ariza, J., & Murillo, Ó. (2019) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2019.01.010 · Cited by 56
Sebbag, L., Allbaugh, R. A., Weaver, A., Seo, Y., & Mochel, J. P. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00752 · Cited by 56
“Such discrepancies likely result in inappropriate dosing, thus affecting the drug efficacy and increasing the risk of toxicity or antimicrobial resistance (Craig, 1998).”
BackgroundTissue and serum concentrations of levofloxacin in orthopaedic patients
von Baum, H., Bøttcher, S. G., Abel, R. F., Gerner, H. J., & Sonntag, H. ‐. (2001) · International Journal of Antimicrobial Agents · doi:10.1016/s0924-8579(01)00423-x · Cited by 56
“Since in a clinical trial with levofloxacin, Preston et al demonstrated that a peakserum/MIC ratio of 12 was predictive of a successful outcome for the patient, it seemed interesting to correlate antibiotic serum and tissue levels with MICs of common pathogens in orthopaedic patients [2,12].”
BackgroundIn Vitro Activities of Six New Fluoroquinolones against Brucella melitensis
Trujillano-Martín, I., García-Sánchez, E., Martínez, I., Fresnadillo, M. J., García‐Sánchez, J. E., & García-Rodríguez, J. Á. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.1.194 · Cited by 56
“melitensis ATCC 23456, because, in general, these new antimicrobial agents have improved pharmacokinetic characteristics (4) and they may have better pharmacokinetic and pharmacodynamic parameters (5).”
BackgroundLodise, T. P., Nau, R., Kinzig, M., Drusano, G. L., Jones, R. N., & Sörgel, F. (2007) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkm325 · Cited by 56
Drusano, G. L., Louie, A., Deziel, M. R., & Gumbo, T. (2006) · Clinical Infectious Diseases · doi:10.1086/499046 · Cited by 56
“[20, 21] has successfully used this model over the past several decades to elucidate pharmacodynamic principles.”
Ertapenem: the new carbapenem 5 years after first FDA licensing for clinical practice
Burkhardt, O., Derendorf, H., & Welte, T. (2007) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.8.2.237 · Cited by 56
“Similar to other β-lactam antibiotics, carbapenems exert their killing effect in a time-dependent manner [81-83].”
BackgroundResultNew Perspectives on Antimicrobial Agents: Imipenem-Relebactam
O’Donnell, J. N., & Lodise, T. P. (2022) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00256-22 · Cited by 55
Pharmacokinetics of Meropenem in Critically Ill Patients With Severe Infections
Binder, L., Schwörer, H., Hoppe, S., Streit, F., Neumann, S., Beckmann, A., Wachter, R., Oellerich, M., & Walson, P. D. (2013) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0b013e31827d496c · Cited by 55
Aerosol antibiotics: considerations in pharmacological and clinical evaluation
Dudley, M. N., Loutit, J. S., & Griffith, D. C. (2008) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2008.11.002 · Cited by 55
Alobaid, A. S., Brinkmann, A., Frey, O. R., Roehr, A. C., Luque, S., Grau, S., Wong, G. Y. M., Abdul-Aziz, M. H., Roberts, M. S., Lipman, J., et al. (2015) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkv412 · Cited by 55
Phagocytes, Antibiotics, and Self-Limiting Bacterial Infections
Levin, B. R., Baquero, F., Ankomah, P., & McCall, I. C. (2017) · Trends in Microbiology · doi:10.1016/j.tim.2017.07.005 · Cited by 55
“For the most part, the recommendations made by proponents of the ‘rational’ (as opposed to purely empirical) approach to antibiotic therapy [30,31] regarding doses and dosing regimens are founded on: (i) pharmacokinetics (PK), almost exclusively estimates of the changes in the concentrations of antibiotics in the seru…”
BackgroundBenítez-Cano, A., Luque, S., Sorlí, L., Carazo, J., Ramos, I., Campillo, N., Curull, V., Sánchez‐Font, A., Vilaplana, C., Horcajada, J. P., et al. (2020) · Critical Care · doi:10.1186/s13054-020-2763-4 · Cited by 55
Potential Antibiotics for the Treatment of Neonatal Sepsis Caused by Multidrug-Resistant Bacteria
Darlow, C. A., da Costa, R. M. A., Ellis, S., Franceschi, F. J., Sharland, M., Piddock, L. J. V., Das, S., & Hope, W. W. (2021) · Pediatric Drugs · doi:10.1007/s40272-021-00465-z · Cited by 55
Odenholt, I. (2001) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.10.6.1157 · Cited by 55
Kobayashi, R., Konomi, M., Hasegawa, K., Morozumi, M., Sunakawa, K., & Ubukata, K. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.3.889-894.2005 · Cited by 55
“As Craig (5) stated, the time above the MIC is generally believed to be the major pharmacokinetic-pharmacodynamic parameter determining the in vivo efficacies of -lactams, unlike aminoglycosides and fluoroquinolones.”
BackgroundDeRyke, C. A., Kuti, J. L., & Nicolau, D. P. (2007) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2007.01.004 · Cited by 55
“These breakpoints represent maximum bactericidal activity based on data obtained from in vitro, animal, or clinical PD studies against Gram-negative bacteria (Craig, 1998; Drusano, 2004; Forrest et al., 1993; Turnidge, 1998; Walker et al., 1994; Wright et al., 2000).”
MethodMichalopoulos, A. S., Kasiakou, S. K., Rosmarakis, E. S., & Falagas, M. E. (2005) · Scandinavian Journal of Infectious Diseases · doi:10.1080/00365540410020776-1 · Cited by 55
“[1] Miller FJ, Ahola DT, Bretzman PA, Fillmore DJ.”
BackgroundCarbon, C., & Poole, M. D. (1999) · Journal of Chemotherapy · doi:10.1179/joc.1999.11.2.107 · Cited by 55
Baietto, L., D’Avolio, A., Rosa, F. G. D., Garazzino, S., Patanella, S., Siccardi, M., Sciandra, M., & Perri, G. D. (2009) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0b013e31819476fa · Cited by 54
Musuka, S., Srivastava, S., Dona, C. W. S., Meek, C. C., Leff, R. D., Pasipanodya, J. G., & Gumbo, T. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00829-13 · Cited by 54
“steady-state pharmacokinetic conditions (%TMIC) (28, 29).”
BackgroundGhazi, I. M., Monogue, M. L., Tsuji, M., & Nicolau, D. P. (2017) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2017.10.008 · Cited by 54
“While in line with the fT>MIC values observed by Nakamura and colleagues [21], the exposure values determined for cefiderocol in the current study are higher than those identified with other β-lactam antibiotics such as ceftazidime 40% fT>MIC for stasis and 60-65 % fT>MIC for maximal killing and cefepime ≥60 % f T>MIC…”
ResultResearch priorities towards precision antibiotic therapy to improve patient care
Bulman, Z. P., Wicha, S. G., Nielsen, E. I., Lenhard, J. R., Nation, R. L., Theuretzbacher, U., Derendorf, H., Tängdén, T., Zeitlinger, M. A., Landersdorfer, C. B., et al. (2022) · The Lancet Microbe · doi:10.1016/s2666-5247(22)00121-5 · Cited by 54
Drug-resistant pneumococcal pneumonia: clinical relevance and approach to management
Fuller, J. D., McGeer, A., & Low, D. E. (2005) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-005-0059-x · Cited by 54
“Pharmacodynamic studies show that the time above the MIC of about 40% of the dosing interval (T>40% MIC) is predictive of bacteriological efficacy for β-lactam agents [ 36 ].Variabilityexistsamongthevariousagentsinregardto their ability to attain a pharmacokinetic/pharmacodynamic target of T>40% MIC for drug-resistant…”
BackgroundOdenholt, I., Gustafsson, I., Löwdin, E., & Cars, O. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.2.518-523.2003 · Cited by 54
“The clinical and microbiological efficacy of -lactam antibiotics seems to correlate with the time that free (non-protein-bound) concentrations exceed the MIC for the infecting pathogen ( 3 , 5, 13).”
BackgroundPea, F., Viale, P., Damiani, D., Pavan, F., Cristini, F., Fanin, R., & Furlanut, M. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.8.3550-3553.2005 · Cited by 54
“Although a t MIC of 50% of the dosing interval may suffice in immunocompetent patients (5), in immunocompromised ones concentrations four to five times the MIC may be needed for maximal bactericidal efficacy with ceftazidime (13).”
BackgroundYadav, H., Yadav, M. K., Jain, S. K., Bhardwaj, A., Singh, V., Parkash, O., & Marotta, F. (2008) · International Journal of Immunopathology and Pharmacology · doi:10.1177/039463200802100427 · Cited by 54
“In India, as well as various other parts of the world, large plants have been used as effective anti-microbials (27).”
BackgroundSun, H. K., Kuti, J. L., & Nicolau, D. P. (2005) · Critical Care Medicine · doi:10.1097/01.ccm.0000181528.88571.9b · Cited by 54
“For comparative purposes, bactericidal targets were defined as 40% T MIC for meropenem and imipenem; 50% T MIC for ceftazidime, cefepime, and piperacillin/tazobactam; and an AUC/MIC ratio of 125 for ciprofloxacin (12, 15, 29, 30).”
BackgroundJacobs, M. R., Bajaksouzian, S., Windau, A., Good, C. E., Lin, G., Pankuch, G. A., & Appelbaum, P. C. (2004) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2004.03.008 · Cited by 54
“An appropriate PK/PD breakpoint for this agent in nonmeningeal infections is 1 lg/mL [19], with 96.”
BackgroundMethodInfluentialBakker‐Woudenberg, I. A. J. M., ten Kate, M. T., Guo, L., Working, P. K., & Mouton, J. W. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.5.1487-1492.2001 · Cited by 54
“Comparative studies of humans with different doses and dosage regimens have also been utilized to optimize antimicrobial treatment (9, 24).”
BackgroundPopulation pharmacokinetics of piperacillin/tazobactam in neonates and young infants
Li, Z., Chen, Y., Li, Q., Cao, D., Shi, W., Cao, Y., Wu, D., Zhu, Y., Wang, Y., & Chen, C. (2013) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-012-1413-4 · Cited by 53
Evangelopoulos, D., da Fonseca, J. D., & Waddell, S. J. (2015) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2014.11.028 · Cited by 53
Antimicrobial chemotherapy and lung microdialysis: a review
Dhanani, J., Roberts, J. A., Chew, M. S., Lipman, J., Boots, R. J., Paterson, D. L., & Fraser, J. F. (2010) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2010.08.013 · Cited by 53
“Current literature describes the PK/PD relationships for ntimicrobial chemotherapy and clinical efficacy [9,10].”
BackgroundShoji, K., Bradley, J. S., Reed, M. D., van den Anker, J. N., Domonoske, C., & Capparelli, E. V. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02592-15 · Cited by 53
“To achieve the maximum bactericidal effect in animal models, 60 to 70% TAM is required, particularly for cephalosporins (27, 28), and several recent articles used 60% TAM of -lactams as their target (25, 29, 30).”
BackgroundThe PK/PD Interactions of Doxycycline against Mycoplasma gallisepticum
Zhang, N., Gu, X., Ye, X., Wu, X., Zhang, B., Zhang, L., Shen, X., Jiang, H., & Ding, H. (2016) · Frontiers in Microbiology · doi:10.3389/fmicb.2016.00653 · Cited by 53
“However, others asserted that, based on visual inspection of killing curve data, it was controversial that the threshold value was 4 MIC (Craig, 1998; Ambrose, 2007).”
BackgroundLepak, A. J., & Andes, D. R. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00647-16 · Cited by 53
“In vivo pharmacodynamic evaluation of antimicrobial activity requires the integration of the aforementioned in vitro potency (MIC), drug pharmacokinetics, and antimicrobial activity over time (21).”
BackgroundMcEntee, L., Johnson, A., Farrington, N., Unsworth, J., Dane, A. L., Jain, A., Cotroneo, N. S., Critchley, I. A., Melnick, D., Parr, T., et al. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00603-19 · Cited by 53
“A well-characterized neutropenic murine thigh infection model was used throughout (20, 32).”
BackgroundMethodRoberts, J. A., Bellomo, R., Cotta, M. O., Koch, B. C. P., Lyster, H. S., Ostermann, M., Roger, C., Shekar, K., Watt, K., & Abdul-Aziz, M. H. (2022) · Intensive Care Medicine · doi:10.1007/s00134-022-06847-2 · Cited by 53
Bidgood, T., & Papich, M. G. (2002) · American Journal of Veterinary Research · doi:10.2460/ajvr.2002.63.1622 · Cited by 53
Ferran, A. A., Kesteman, A.-S., Toutain, P., & Bousquet‐mélou, A. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01347-08 · Cited by 53
“Traditionally, in vitro 38 antimicrobial studies and animal infection models have been used to assess the reduction in 39 the total bacterial population at an infectious site while often ignoring the impact of drug 40 pressure on amplification of the drug-resistant subpopulation (7).”
MethodFehér, C., Rovira, M., Soriano, À., Esteve, J., Martínez, J. A., Marco, F., Carreras, E., Martínez, C., Fernández‐Avilés, F., Suárez‐Lledó, M., et al. (2014) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dku150 · Cited by 53
New Formulations of Amoxicillin/Clavulanic Acid: A Pharmacokinetic and Pharmacodynamic Review
Navarro, A. S. (2005) · Clinical Pharmacokinetics · doi:10.2165/00003088-200544110-00001 · Cited by 53
“[60] It has It is generally accepted that amoxicillin produces been postulated that the size of the T>MIC that best a post-antibacterial effect (PAE) of short duration correlates with clinical outcome in mild to moderate (1.”
BackgroundArrieta, A. C., Arguedas, A. G., Fernández, P., Block, S. L., Emperanza, P., Vargas, S. L., Erhardt, W., de Caprariis, P. J., & Rothermel, C. D. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.10.3179-3186.2003 · Cited by 53
“These recommendations are based on (i) pharmacokinetic and pharmacodynamic data (9, 10), (ii) results of a recent double tympanocentesis (“double-tap”) study (13), and (iii) the concept that the addition of clavulanate to amoxicillin will uniformly inactivate -lactamase produced by strains of H.”
BackgroundOutcomes in lower respiratory tract infections and the impact of antimicrobial drug resistance
Metlay, J. P., & Singer, D. E. (2002) · Clinical Microbiology and Infection · doi:10.1046/j.1469-0691.8.s.2.4.x · Cited by 53
“not necessarily reflect true drug levels in vivo [21].”
BackgroundBock, M., Theut, A. M., van Hasselt, J. G. C., Wang, H., Fuursted, K., Høiby, N., Lerche, C. J., Ihlemann, N., Gill, S. U. A., Christiansen, U., et al. (2023) · Clinical Infectious Diseases · doi:10.1093/cid/ciad168 · Cited by 52
Bensman, T. J., Wang, J., Jayne, J. G., Fukushima, L., Rao, A. P., D’Argenio, D. Z., & Beringer, P. M. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00988-17 · Cited by 52
“In an exploratory analysis, we also selected stasis (fT MIC, 40%), nearly maximal killing (fT MIC, 65%), and maximal killing (fT MIC, 100%) to be the PD targets for CAZ defined by previous clinical infection models (33) as well as preclinical infection models (34, 35) in which treatment with other cephalosporins was u…”
MethodAvery, L. M., Abdelraouf, K., & Nicolau, D. P. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00948-18 · Cited by 52
Management of Antimicrobial Use in the Intensive Care Unit
Álvarez-Lerma, F., & Grau, S. (2012) · Drugs · doi:10.2165/11599520-000000000-00000 · Cited by 52
Effect of Optimized Antibiotic Prophylaxis on the Incidence of Surgical Site Infection
Manniën, J., van Kasteren, M. E. E., Nagelkerke, N. J. D., Gyssens, I. C., Kullberg, B. J., Wille, J. C., & de Boer, A. S. (2006) · Infection Control and Hospital Epidemiology · doi:10.1017/s0195941700075275 · Cited by 52
Pichichero, M. E., Reiner, S. A., Yamauchi, T., Brook, I., Jenkins, S. G., Gooch, W. M., & Sher, L. (2000) · Annals of Otology Rhinology & Laryngology · doi:10.1177/00034894001090s801 · Cited by 52
Methicillin-Resistant Staphylococcus Aureus: Impact on Dermatology Practice
Gosbell, I. B. (2004) · American Journal of Clinical Dermatology · doi:10.2165/00128071-200405040-00004 · Cited by 51
the Inter-Michinoku Dasatinib Study Group (IMIDAS), Ishida, Y., Murai, K., Yamaguchi, K., Miyagishima, T., Shindo, M., Ogawa, K., Nagashima, T., Sato, S., Watanabe, R., et al. (2015) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-015-1968-y · Cited by 51
Takahashi, S., Ichihara, K., Hashimoto, J., Kurimura, Y., Tsukamoto, T., Iwasawa, A., Hayashi, K., Sunaoshi, K., Takeda, K., Suzuki, N., et al. (2010) · Journal of Infection and Chemotherapy · doi:10.1007/s10156-010-0192-z · Cited by 51
“antimicrobials [3], and 500-mg LVFX tablets were already available in Europe and the USA.”
BackgroundLiang, B., Bai, N., Cai, Y., Wang, R., Drlica, K., & Zhao, X. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00975-10 · Cited by 51
“Since MIC-based pharmacokinetic/pharmacodynamic (PK/ PD) indices have successfully been used to predict microbiological outcome for the bulk of the bacterial population (5, 15, 17, 18), attempts have also been made to use MIC-based indices to establish PK/PD targets for the design of dosing regimens that limit selecti…”
MethodPharmacodynamics of Cefquinome in a Neutropenic Mouse Thigh Model of Staphylococcus aureus Infection
Wang, J., Shan, Q., Ding, H., Liang, C., & Zeng, Z. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01666-13 · Cited by 51
“Numerous in vitro and in vivo models and clinical trials have suggested that the magnitude of the %T MIC predictive of cephalosporin efficacy ranges from 25 to 70%, depending upon the defined therapeutic endpoint (15, 30, 31).”
BackgroundMonogue, M. L., Pettit, R. S., Muhlebach, M. S., Cies, J. J., Nicolau, D. P., & Kuti, J. L. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01566-16 · Cited by 51
Metadata
- Authors
- Craig, W. A.
- Affiliations
- William S. Middleton Memorial Veterans Hospital (US)
- Corresponding author
- Craig, William A.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 1998-01
- Volume
- 26
- Issue
- 1
- Pages
- 1-10
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2113717321
- Cited by
- 2,908
- References
- 50
- Citations by year
- 2026: 68 · 2025: 81 · 2024: 82 · 2023: 99 · 2022: 86 · 2021: 89 · 2020: 103 · 2019: 94 · 2018: 105 · 2017: 124 · 2016: 136 · 2015: 113 · 2014: 129 · 2013: 109 · 2012: 101
- FWCI
- 54.89
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Infectious Diseases (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Antibiotics Pharmacokinetics and Efficacy
- Health Sciences › Medicine › Infectious Diseases › Antibiotic Use and Resistance
- Health Sciences › Medicine › Microbiology (medical) › Antibiotic Resistance in Bacteria
- Keywords
- pharmacokinetics/pharmacodynamics, dosing regimen, pharmacodynamic parameters, pharmacokinetic parameters, animal models of infection, human infection, susceptibility breakpoints, antimicrobial resistance, emerging pathogens, drug development costs
- MeSH terms
- Animals, Anti-Bacterial Agents, Bacteria, Humans, Lactams, Microbial Sensitivity Tests, Fluoroquinolones
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.